SE8701004D0 - Method for therapy of leukemias and certain other malignancies - Google Patents

Method for therapy of leukemias and certain other malignancies

Info

Publication number
SE8701004D0
SE8701004D0 SE8701004A SE8701004A SE8701004D0 SE 8701004 D0 SE8701004 D0 SE 8701004D0 SE 8701004 A SE8701004 A SE 8701004A SE 8701004 A SE8701004 A SE 8701004A SE 8701004 D0 SE8701004 D0 SE 8701004D0
Authority
SE
Sweden
Prior art keywords
leukemias
malignancies
therapy
certain
man
Prior art date
Application number
SE8701004A
Other languages
English (en)
Inventor
M Jondal
A Rosen
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE8701004A priority Critical patent/SE8701004D0/sv
Publication of SE8701004D0 publication Critical patent/SE8701004D0/sv
Priority to EP88902603A priority patent/EP0305468A1/en
Priority to PCT/SE1988/000118 priority patent/WO1988006891A1/en
Priority to JP63502593A priority patent/JPH01502592A/ja
Priority to AU14878/88A priority patent/AU621046B2/en
Priority to FI885177A priority patent/FI885177A/fi
Priority to NO885015A priority patent/NO885015L/no
Priority to DK626788A priority patent/DK626788D0/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8701004A 1987-03-11 1987-03-11 Method for therapy of leukemias and certain other malignancies SE8701004D0 (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE8701004A SE8701004D0 (sv) 1987-03-11 1987-03-11 Method for therapy of leukemias and certain other malignancies
EP88902603A EP0305468A1 (en) 1987-03-11 1988-03-10 B-cell growth and differentiating factor BCGF 12K for use in therapy
PCT/SE1988/000118 WO1988006891A1 (en) 1987-03-11 1988-03-10 Method for therapy of leukemias and certain other malignancies
JP63502593A JPH01502592A (ja) 1987-03-11 1988-03-10 白血病およびある種の悪性腫瘍の治療方法
AU14878/88A AU621046B2 (en) 1987-03-11 1988-03-10 Method for therapy of leukemias and certain other malignancies
FI885177A FI885177A (fi) 1987-03-11 1988-11-10 Foerfarande foer behandling av leukemier och vissa andra former av cancer.
NO885015A NO885015L (no) 1987-03-11 1988-11-10 Fremgangsmaate for terapi av leukemier og visse andre ondartetheter.
DK626788A DK626788D0 (da) 1987-03-11 1988-11-10 Framgangsmaade til behandling af leukaemier og visse andre maligne tilstande

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8701004A SE8701004D0 (sv) 1987-03-11 1987-03-11 Method for therapy of leukemias and certain other malignancies

Publications (1)

Publication Number Publication Date
SE8701004D0 true SE8701004D0 (sv) 1987-03-11

Family

ID=20367826

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8701004A SE8701004D0 (sv) 1987-03-11 1987-03-11 Method for therapy of leukemias and certain other malignancies

Country Status (6)

Country Link
EP (1) EP0305468A1 (sv)
JP (1) JPH01502592A (sv)
AU (1) AU621046B2 (sv)
FI (1) FI885177A (sv)
SE (1) SE8701004D0 (sv)
WO (1) WO1988006891A1 (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
KR100191223B1 (ko) * 1989-07-28 1999-06-15 둘락 노먼 씨. 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
GB9001625D0 (en) * 1990-01-24 1990-03-21 Ciba Geigy Ag A pharmaceutical preparation for maturation of prothymocytes
GB9010356D0 (en) * 1990-05-09 1990-06-27 Ciba Geigy Ag Maturation of hemopoietic cells
JPH06502644A (ja) * 1990-11-16 1994-03-24 シェリング・コーポレーション インターロイキン５による単球および好中球の増加および活性化法および骨髄細胞の成熟誘導法
WO1993005801A1 (en) * 1991-09-16 1993-04-01 Schering Corporation Use of il-5 to treat solid tumors
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP3426271A4 (en) 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077571A3 (en) * 1981-10-19 1983-10-12 Ajinomoto Co., Inc. Process for producing a lymphokine
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4882282A (en) * 1985-08-16 1989-11-21 Immunex Corporation DNA sequences encoding bovine interleukin-2
JPH0763361B2 (ja) * 1985-10-15 1995-07-12 三井東圧化学株式会社 培養株化細胞株
IL80678A (en) * 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
EP0256042A1 (en) * 1986-01-15 1988-02-24 AMERSHAM INTERNATIONAL plc Interleukin
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
AU603820B2 (en) * 1986-08-13 1990-11-29 Takeda Chemical Industries Ltd. Antitumor agent

Also Published As

Publication number Publication date
EP0305468A1 (en) 1989-03-08
WO1988006891A1 (en) 1988-09-22
AU621046B2 (en) 1992-03-05
FI885177A0 (fi) 1988-11-10
FI885177A (fi) 1988-11-10
AU1487888A (en) 1988-10-10
JPH01502592A (ja) 1989-09-07

Similar Documents

Publication Publication Date Title
SE8701004D0 (sv) Method for therapy of leukemias and certain other malignancies
IT1208521B (it) Elettrodo, apparecchiatura e defibrillazione per l'impianto in corpi umani o animali.
GR880300077T1 (en) Galanthamine or analogues thereof for treating alzheimer's disease
DE69009280T2 (de) Einpflanzbare Vorrichtung mit 24-Stunden-Rhythmussteuerung.
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
EP0276536A3 (en) Use of buspirone for the improvement of short term memory
AU8091787A (en) The use of paroxetine to treat pain
EP0228448A4 (en) Use of biologically active copolymers for the manufacture of a medicament for stimulating the growth of animals.
GB8704190D0 (en) Therapeutic agent
MY104006A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
DE3361812D1 (en) Antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
GR3018869T3 (en) Use of paf-antagonists for the preparation of a medicament and method for the determination of their binding-activity
GB2211389B (en) Procedure for the treatment of pigs in slaughterhouses, and system for the stalling of pigs
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
ZA872128B (en) Chlorpheniramine therapy
EP0204954A3 (en) Use of dopamine agonists in the treatment of psychostimulant addiction
ZA857721B (en) Process for treatment of rheumatic diseases
AU2661588A (en) Method for treating hoof thrush and hoof rot
ZA837972B (en) Method of analgesic treatment and pharmaceutical compositions
ES469908A1 (es) Procedimiento de utilizacion de salinomicina.
PT91610A (pt) Process for the preparation of compounds for the treatment of arteritis rheumatoidal
IT8720800A0 (it) Composto attivo nella terapia carciovascolare.
GR3002328T3 (en) 2-(benzhydrylsulfonyl) acetamide, process for its preparation and its therapeutical use